Kronos: AML data does not support continuing to phase 2

 Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2

New development candidate KB-9558 inhibits the KAT domain of p300 and thereby modulates IRF4, a key driver of multiple myeloma; IND-enabling studies underway for expected completion in Q4 2024

Kronos Bio’s first development candidate, KB-0742, cleared 80 mg dose in dose escalation portion of the phase 1/2 trial; trial progresses in solid tumor expansion cohorts

Expected cash runway maintained into 2026 

https://www.globenewswire.com/news-release/2023/12/18/2798137/0/en/Kronos-Bio-Announces-Pipeline-Update-and-p300-KAT-Inhibitor-Development-Candidate.html